![Dr. Reddy's shares rise 3% on buying Haleon’s nicotine gum biz; here’s what brokerages say](https://images.assettype.com/fortuneindia%2F2024-06%2F9bcd50f8-d291-4a99-b09c-c500e0bde2f0%2Fhaleon.jpeg?w=300&q=95)
Dr. Reddy's shares rise 3% on buying Haleon’s nicotine gum biz; here’s what brokerages say
The pharma major has agreed to acquire Haleon Plc’s Nicotinell and related portfolio outside of the U.S., for 500 million pounds.
The pharma major has agreed to acquire Haleon Plc’s Nicotinell and related portfolio outside of the U.S., for 500 million pounds.
The USFDA has issued a letter for violations of Current Good Manufacturing Practice (cGMP) regulations at Sun Pharma’s Dadra facility.
The board of the homegrown pharma company has approved raising of funds worth ₹7,500 crore via issuance of equity shares.
The promoter group sold 2.53% stake in Cipla, worth around ₹2,637 crore, via block deal today.
In the January to March quarter of FY24, Piramal Pharma’s revenue from operations grew 18% to ₹2,552 crore as against ₹2,164 crore in the corresponding period of the previous year.
The Drugs Controller General of India, Rajeev Singh Raghuvanshi, stated that the decision was taken to facilitate the application process for the industry.
The pharma company has received approval to manufacture and market Mometasone Furoate Monohydrate Nasal Spray 50 mcg, which will be launched in Q1 FY25.
The innovation segment is dominated by pharma services (CDMO, CRO, pharma IT) and health-tech with vaccines and biotech, and med-tech emerging as green shoots
The USFDA conducted the pre-approval inspection at the company’s oral-oncology manufacturing facility situated in Bileshwarpura, Gujarat from December 5 to December 11 last year.
The industry expects an enhanced healthcare spend of 2.5% of GDP to boost infrastructure and R&D activities.